Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study

BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Eur Acad Dermatol Venereol
Main Authors: Gerdes, S., Thaçi, D., Griffiths, C.E.M., Arenberger, P., Poetzl, J., Wuerth, G., Afonso, M., Woehling, H.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Original Articles and Short Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887937/
https://ncbi.nlm.nih.gov/pubmed/28960486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14605
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki